Abstract
There is overwhelming evidence that the brain melanocortin system is a key regulator of energy balance, and dysregulations in the brain melanocortin system can lead to obesity. The melanocortin system is one of the major downstream leptin signaling pathways in the brain. In contrast to leptin, preclinical studies indicate that diet-induced obese animals are still responsive to the anorectic effects of melanocortin receptor agonists, suggesting the melanocortin system is an interesting therapeutic opportunity. Besides regulating energy balance, melanocortins are involved in a variety of other neuroendocrine processes, including inflammation, blood pressure regulation, addictive and sexual behavior, and sensation of pain. This review evaluates the melanocortin system function from the perspective to use specific melanocortin (MC) receptors as drug targets, with a focus on the treatment of obesity and eating disorders in humans, and the implications this may have on mechanisms beyond the control of energy balance.
Keywords: pro-opiomelanocortin (POMC) gene, melanocortin (MC)receptors, MC4 receptor knockout mice, diet-induced obesity prone (DIO-P)rats, Obesity
CNS & Neurological Disorders - Drug Targets
Title: Melanocortin Receptors as Drug Targets for Disorders of Energy Balance
Volume: 5 Issue: 3
Author(s): Roger A.H Adan and Gertjan v. Dijk
Affiliation:
Keywords: pro-opiomelanocortin (POMC) gene, melanocortin (MC)receptors, MC4 receptor knockout mice, diet-induced obesity prone (DIO-P)rats, Obesity
Abstract: There is overwhelming evidence that the brain melanocortin system is a key regulator of energy balance, and dysregulations in the brain melanocortin system can lead to obesity. The melanocortin system is one of the major downstream leptin signaling pathways in the brain. In contrast to leptin, preclinical studies indicate that diet-induced obese animals are still responsive to the anorectic effects of melanocortin receptor agonists, suggesting the melanocortin system is an interesting therapeutic opportunity. Besides regulating energy balance, melanocortins are involved in a variety of other neuroendocrine processes, including inflammation, blood pressure regulation, addictive and sexual behavior, and sensation of pain. This review evaluates the melanocortin system function from the perspective to use specific melanocortin (MC) receptors as drug targets, with a focus on the treatment of obesity and eating disorders in humans, and the implications this may have on mechanisms beyond the control of energy balance.
Export Options
About this article
Cite this article as:
Adan A.H Roger and Dijk v. Gertjan, Melanocortin Receptors as Drug Targets for Disorders of Energy Balance, CNS & Neurological Disorders - Drug Targets 2006; 5(3) . https://dx.doi.org/10.2174/187152706777452290
DOI https://dx.doi.org/10.2174/187152706777452290 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Follow-Up of Dietary Treatment of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Biomarkers and Cellular Signal Detection for Alzheimer’s Disease, Stroke, and Immune System Mediated Disorders
Current Neurovascular Research Plant Extracts and their Secondary Metabolites as Modulators of Kinases
Current Topics in Medicinal Chemistry Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Organizational Impact of the Introduction of a New Portable Syringe Pump for Iloprost Therapy in Italian Hospital Settings
Current Drug Therapy Pathophysiology of Coronary Collaterals
Current Cardiology Reviews Pharmacological Management of PDA: Oral Versus Intravenous Medications
Current Clinical Pharmacology Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Microwave-Promoted One-Pot Three-Component Synthesis of 1-Amidoalkyl-2-Carbazolol Derivatives
Letters in Organic Chemistry Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Subject Index to Volume 9
Current Pharmaceutical Design Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry